The retrospective, observational RWD-ACROSS study analyzed disease characteristics, systemic treatment, and survival in patients with metastatic colorectal cancer (mCRC) in Spain. In total, 2002 patients were enrolled (mean age 65.3 years; 62.7% male). Overall median overall survival (OS) was 26.72 months, and was longer in patients with left-sided tumors (28.85 vs. 21.04 months (right-sided tumors);p <0.0001) and in patients receiving first-line anti-epidermal growth factor receptor (EGFR) treatment (31.21 vs. 26.75 (anti-vascular endothelial growth factor (VEGF) treatment) and 24.45 months (chemotherapy);p =0.002). Overall median progression-free survival (PFS) was 10.72 months and was longer in patients with left-sided tumors (11.24 vs. 9.31 months (right-sided tumors);p <0.0001), and in patients receiving either first-line anti-EGFR or anti-VEGF (12.13 and 12.00 vs. 8.98 months (chemotherapy);p <0.001). PFS was longer with anti-VEGF treatment in patients with right-sided tumors and wild-typeRAS(11.24 vs. 8.78 (anti-EGFR) and 7.83 months (chemotherapy);p =0.025). Both anti-EGFR and anti-VEGF produced longer PFS in patients with left-sided tumors and wild-typeRASthan chemotherapy alone (12.39 and 13.14 vs. 9.83 months;p =0.011). In patients with left-sided tumors and mutantRAS, anti-VEGF produced a longer PFS than chemotherapy alone (12.36 vs. 9.34 months;p =0.001). In Spain, wild-typeRASor left-sided mCRC tumors are predictive of longer survival times.
回顾性观察研究RWD-ACROSS分析了西班牙转移性结直肠癌（mCRC）患者的疾病特征、系统治疗及生存情况。研究共纳入2002例患者（平均年龄65.3岁；男性占62.7%）。总体中位总生存期（OS）为26.72个月，其中左侧肿瘤患者生存期更长（28.85个月 vs. 右侧肿瘤21.04个月；p <0.0001），接受一线抗表皮生长因子受体（EGFR）治疗的患者生存期也更长（31.21个月 vs. 抗血管内皮生长因子（VEGF）治疗26.75个月 vs. 单纯化疗24.45个月；p =0.002）。总体中位无进展生存期（PFS）为10.72个月，左侧肿瘤患者（11.24个月 vs. 右侧肿瘤9.31个月；p <0.0001）以及接受一线抗EGFR或抗VEGF治疗的患者（12.13个月和12.00个月 vs. 单纯化疗8.98个月；p <0.001）PFS更长。在右侧肿瘤且RAS野生型患者中，抗VEGF治疗的PFS更长（11.24个月 vs. 抗EGFR治疗8.78个月 vs. 单纯化疗7.83个月；p =0.025）。对于左侧肿瘤且RAS野生型患者，抗EGFR和抗VEGF治疗均比单纯化疗获得更长的PFS（12.39个月和13.14个月 vs. 9.83个月；p =0.011）。在左侧肿瘤且RAS突变型患者中，抗VEGF治疗比单纯化疗PFS更长（12.36个月 vs. 9.34个月；p =0.001）。在西班牙，RAS野生型或左侧mCRC肿瘤可预测更长的生存时间。
Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study
肿瘤(癌症)患者之家